TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6608327

Group type: EXPERIMENTAL
Intervention: Continuous intercostal nerve block for five days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anterolateral thoracotomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 20
Study: 31698420

Group type: EXPERIMENTAL
Intervention: Genomic and transcriptomic association of 16 novel susceptibility loci for VTE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 0
Study: 28575490

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided (USG) venipuncture
Number of subjects: 320

Group type: COMPARATOR
Intervention: Conventional venipuncture
Number of subjects: 320
Study: 24571169

Group type: EXPERIMENTAL
Intervention: Probiotics, taken twice a day for 2 weeks before surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo, taken twice a day for 2 weeks before surgery
Number of subjects: 30
Study: 24958486

Group type: EXPERIMENTAL
Intervention: TURis system
Number of subjects: 136

Group type: COMPARATOR
Intervention: Conventional monopolar technique
Number of subjects: 136
Study: 22753904

Group type: EXPERIMENTAL
Intervention: Dose-escalated cetuximab (500 mg/m2 per week)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Standard-dose cetuximab (400 mg/m2 initial dose, then 250 mg/m2 per week)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Dose-escalated cetuximab (500 mg/m2 per week) in KRAS wild-type tumors
Number of subjects: 157

Group type: COMPARATOR
Intervention: Standard-dose cetuximab (400 mg/m2 initial dose, then 250 mg/m2 per week) in KRAS wild-type tumors
Number of subjects: 157
Study: 20444847

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy with carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 15-3 monitoring
Number of subjects: 63
Study: 17013650

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Amodiaquine-sulfalene-pyrimethamine (ASP)
Number of subjects: 181
Study: 16150198

Group type: EXPERIMENTAL
Intervention: Gankangyin (GKY) for 3 months
Number of subjects: 96

Group type: COMPARATOR
Intervention: Silymarin for 3 months
Number of subjects: 96
Study: 12114886

Group type: EXPERIMENTAL
Intervention: Duloxetine 20 mg/day
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg/day
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg/day
Number of subjects: 553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Duloxetine (all doses) in severe cases
Number of subjects: 553
Study: 11035129

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (300 mg b.d.)
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg t.d.s.)
Number of subjects: 812

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid and Indomethacin
Number of subjects: 812

Group type: COMPARATOR
Intervention: Tiaprofenic acid and Placebo
Number of subjects: 812
Study: 8633584

Group type: EXPERIMENTAL
Intervention: Regimen 1 (B 150 mg q.i.d., OT 500 mg q.i.d., M 400 mg t.i.d. for 10 days and R 300 mg b.i.d. for 4 wk)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Regimen 2 (same as regimen 1 except ranitidine)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Regimen 3 (same as regimen 1 except metronidazole)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Regimen 4 (same as regimen 1 except metronidazole and ranitidine)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Regimens 1+2 (with metronidazole)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Regimens 1+3 (with ranitidine)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Regimens 2+4 (without ranitidine)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ranitidine (during therapy)
Number of subjects: 180
Study: 1572471

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3985430

Group type: COMPARATOR
Intervention: Enflurane at an inspired concentration of 2.5% during hypothermia (28 degrees C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enflurane during hypothermic CPB
Number of subjects: 0
Study: 30979409

Group type: EXPERIMENTAL
Intervention: Positive Psychology-Motivational Interviewing (PP-MI)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Attention-matched, MI-based health education control
Number of subjects: 47
Study: 29754666

Group type: EXPERIMENTAL
Intervention: Bucindolol hydrochloride
Number of subjects: 620

Group type: COMPARATOR
Intervention: Metoprolol succinate
Number of subjects: 620
Study: 26176643

Group type: EXPERIMENTAL
Intervention: Aliskiren (150-300 mg)/Amlodipine (5 mg) (ALI/AML group, n=53)
Number of subjects: 105

Group type: COMPARATOR
Intervention: High-dose Amlodipine (10 mg) (h-dAML group, n=52)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both ALI/AML and h-dAML groups
Number of subjects: 105
Study: 24762158

Group type: EXPERIMENTAL
Intervention: Biceps repair
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Biceps tenodesis
Number of subjects: 37
Study: 22429255

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 20226329

Group type: EXPERIMENTAL
Intervention: Clarithromycin regimen
Number of subjects: 4372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4372
Study: 17470315

Group type: EXPERIMENTAL
Intervention: ondansetron (0.25 mg, 1 mg, or 4 mg b.i.d.)
Number of subjects: 150

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 150
Study: 15933930

Group type: EXPERIMENTAL
Intervention: Transnasal esophagoscopy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Transoral esophagoscopy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional endoscopy (sedated)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 4-mm video esophagoscope
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Preprocedure anxiety
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 90
Study: 12364985

Group type: EXPERIMENTAL
Intervention: KTP laser ablation after anti-reflux surgery
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fundoplication alone
Number of subjects: 9
Study: 10486789

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: HRT/ERT
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (untreated women)
Number of subjects: 148
Study: 9138995

Group type: EXPERIMENTAL
Intervention: Forceps delivery
Number of subjects: 170

Group type: COMPARATOR
Intervention: Normal vaginal delivery
Number of subjects: 170
Study: 30094885

Group type: EXPERIMENTAL
Intervention: Vaginal washing before intravaginal dinoprostone insertion (10 mg dinoprostone via Propess system)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (no vaginal washing before intravaginal dinoprostone insertion)
Number of subjects: 191
Study: 26990824

Group type: EXPERIMENTAL
Intervention: Early integrated ART initiation during TB treatment
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Late integrated ART initiation during TB treatment
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Delayed ART initiation after TB treatment completion
Number of subjects: 642

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 642
Study: 24902992

Group type: EXPERIMENTAL
Intervention: Football Training (FTG)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Strength Training (STG)
Number of subjects: 26
Study: 22387008

Group type: EXPERIMENTAL
Intervention: 50% discount on healthy foods
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 25% discount on healthy foods
Number of subjects: 150

Group type: COMPARATOR
Intervention: No discount on healthy foods
Number of subjects: 150

Group type: COMPARATOR
Intervention: Price increases on unhealthy foods (5%, 10%, 25%)
Number of subjects: 150
Study: 20048658

Group type: EXPERIMENTAL
Intervention: Intraoperative thoracic epidural bupivacaine perfusion (0.5% at 3 mL/hr) with preoperative intrathecal morphine (0.5 mg) and fentanyl (15 microg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (sham epidural) with the same intrathecal narcotics
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intraoperative thoracic epidural bupivacaine
Number of subjects: 44
Study: 17968337

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advanced analytical techniques
Number of subjects: 0
Study: 15864023

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study: 12472591

Group type: EXPERIMENTAL
Intervention: Subcutaneous lenograstim during the first 12 weeks of standard immunosuppressive therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy (control group)
Number of subjects: 102
Study: 9619322

Group type: EXPERIMENTAL
Intervention: E-5510
Number of subjects: 7

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 7
Study: 8749707

Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulins (IVIg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Plasma exchange (PE) and Intravenous immune globulins (IVIg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Single therapy (either PE or IVIg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Second cycle of therapy (either PE or IVIg)
Number of subjects: 36
Study: 2494973

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 97

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 97
Study: 324571

Group type: EXPERIMENTAL
Intervention: Single preoperative dose of cephazolin
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Single preoperative dose of cephazolin plus a five-day course postoperatively
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (no cephazolin)
Number of subjects: 201
Study: 29205165

Group type: EXPERIMENTAL
Intervention: Routine ciprofloxacin prophylaxis (Group 1, n=156)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Targeted prophylactic antibiotic regime (Group 2, n=144)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Targeted prophylactic antibiotic regime (Group 2)
Number of subjects: 300
Study: 25726497

Group type: EXPERIMENTAL
Intervention: Active DBS treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham DBS treatment
Number of subjects: 30
Study: 24460318

Group type: EXPERIMENTAL
Intervention: Evidence-Based Intervention (EBI)
Number of subjects: 232
Study: 21504934

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided TAP blocks
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (no TAP blocks)
Number of subjects: 93
Study: 19804515

Group type: EXPERIMENTAL
Intervention: Adenosine (12 mg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Verapamil (10 mg)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 74

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 74
Study: 17057049

Group type: EXPERIMENTAL
Intervention: Pharmacist-managed diabetes care program
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard diabetes care (Control)
Number of subjects: 149
Study: 12635025

Group type: EXPERIMENTAL
Intervention: valsartan alone or combined with hydrochlorothiazide
Number of subjects: 11447
Study: 11783325

Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (TCM-WM) treatment including prednisone, Cytoxan (CTX), and Chinese medicinal herbs according to Syndrome-type.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group treated with Western medicine (WM) alone.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Integrated traditional Chinese and Western medicine (TCM-WM) treatment.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups.
Number of subjects: 82
Study: 9166162

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 24

Group type: COMPARATOR
Intervention: Medroxyprogesterone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1589731

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 82
Study: 3899240

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMW heparin) 1850 APTT units (7500 antifactor Xa units)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Unfractionated (UF) calcium heparin 10000 APTT units
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Single injection of LMW heparin every day
Number of subjects: 395
Study: 30382820

Group type: EXPERIMENTAL
Intervention: Women referred with obstructed labor
Number of subjects: 84924

Group type: EXPERIMENTAL
Intervention: Grand multiparity (> 5 live births)
Number of subjects: 84924

Group type: EXPERIMENTAL
Intervention: Prior cesarean
Number of subjects: 84924

Group type: EXPERIMENTAL
Intervention: Resides outside hospital region
Number of subjects: 84924

Group type: EXPERIMENTAL
Intervention: No prenatal care visits
Number of subjects: 84924

Group type: EXPERIMENTAL
Intervention: Birth weight of > 3600 g
Number of subjects: 84924
Study: 27245485

Group type: EXPERIMENTAL
Intervention: Continuation of elastic compression stockings (ECS) for 24 months after diagnosis of deep venous thrombosis.
Number of subjects: 518

Group type: COMPARATOR
Intervention: Stopping elastic compression stockings (ECS) after 12 months.
Number of subjects: 518

Group type: COMPARATOR
Intervention: Continuation of ECS for 24 months versus stopping ECS after 12 months.
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Quality of life (VEINES-QOL/Sym) assessment.
Number of subjects: 518
Study: 24068750

Group type: EXPERIMENTAL
Intervention: Combined cognitive-behavioral psychotherapy (14 one-hour weekly sessions)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional cognitive-behavioral psychotherapy (14 one-hour weekly sessions)
Number of subjects: 25
Study: 22673017

Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH(4)) 10 mg·kg(‐1) body weight
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 20064056

Group type: EXPERIMENTAL
Intervention: Web‐based personal health site (Mellen Center Care On‐line) for self-management of multiple sclerosis symptoms
Number of subjects: 2041

Group type: COMPARATOR
Intervention: Patient nonresponders (PNR)
Number of subjects: 2041
Study: 19001248

Group type: EXPERIMENTAL
Intervention: Carisbamate 300 mg/d
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Carisbamate 800 mg/d
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Carisbamate 1,600 mg/d
Number of subjects: 537

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study: 15746990

Group type: EXPERIMENTAL
Intervention: Weight loss with normal calcium intake (1 g/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Weight loss with high calcium intake (1.7 g/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Weight maintenance with normal calcium intake (1 g/day)
Number of subjects: 66
Study: 11931600

Group type: EXPERIMENTAL
Intervention: Compliance enhancement intervention using a problem-solving format
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard disposition planning
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Compliance enhancement intervention using a problem-solving format (after covarying barriers)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard disposition planning (after covarying barriers)
Number of subjects: 63
Study: 10467203

Group type: EXPERIMENTAL
Intervention: saruplase
Number of subjects: 255

Group type: COMPARATOR
Intervention: streptokinase
Number of subjects: 255
Study: 8750419

Group type: EXPERIMENTAL
Intervention: Letter insertion task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letter deletion task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Process dissociation paradigm applied to letter insertion task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exclusion condition in letter insertion task
Number of subjects: 0
Study: 2141110

Group type: EXPERIMENTAL
Intervention: Sequential ultrafiltration (UF; 1 litre/h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Biochemical correction (BC; 3 h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Biochemical correction (BC) during BC-UF
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sequential ultrafiltration (UF) during BC-UF
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sequential ultrafiltration (UF)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Biochemical correction (BC) in UF-BC sequence
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Biochemical correction (BC)
Number of subjects: 8
Study: 6109648

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg every eight hours for a maximum of three days during menstruation for three consecutive cycles)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 30073784

Group type: EXPERIMENTAL
Intervention: Web-Based Diabetes Training Program (WB-DTP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 30442174

Group type: COMPARATOR
Intervention: Standard dissemination
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Type 1 facilitation
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Type 2 facilitation
Number of subjects: 2313
Study: 28024268

Group type: EXPERIMENTAL
Intervention: Stressor group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25294277

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 1049
Study: 24534317

Group type: EXPERIMENTAL
Intervention: Remifentanyl and propofol injection (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxycodone hydrochloride (Group B)
Number of subjects: 60
Study: 20376076

Group type: EXPERIMENTAL
Intervention: nebivolol (5-10 mg/day) for 8 weeks
Number of subjects: 43
Study: 18362593

Group type: EXPERIMENTAL
Intervention: LMA CTrach
Number of subjects: 271

Group type: COMPARATOR
Intervention: LMA Fastrach
Number of subjects: 271
Study: 17395027

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group not explicitly mentioned)
Number of subjects: 0
Study: 12699210

Group type: EXPERIMENTAL
Intervention: Combination of glucocorticoid and beta‐agonist (n = 52)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control children of the same age (n = 20)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Glucocorticoid alone (n = 23)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Beta‐agonist alone (n = 11)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Children in group 1 with C/U ratio above 6 (n = 24)
Number of subjects: 129
Study: 11084569

Group type: EXPERIMENTAL
Intervention: Overlap repair
Number of subjects: 112

Group type: COMPARATOR
Intervention: Approximation repair
Number of subjects: 112
Study: 9378464

Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy (CT) for ALL
Number of subjects: 31
Study: 7901258

Group type: COMPARATOR
Intervention: Dapiprazole administered as directed by its manufacturer after pupil dilation with proparacaine 0.5%, hydroxyamphetamine 1.0%, and tropicamide 0.25%.
Number of subjects: 26
Study: 3961029

Group type: EXPERIMENTAL
Intervention: S-adenosyl-methionine (SAMe) 400 mg single dose and seven daily administrations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic treatment with monoamine oxidase inhibitors (MAOIs)
Number of subjects: 0
Study: 31112543

Group type: EXPERIMENTAL
Intervention: Community-based adherence clubs
Number of subjects: 775

Group type: COMPARATOR
Intervention: Clinic-based adherence clubs
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Both groups (lost from club-based care)
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Both groups (referred to standard care)
Number of subjects: 775
Study: 30290675

Group type: EXPERIMENTAL
Intervention: FDA pivotal trials
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CMS original trials
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FDA approvals
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CMS NCDs
Number of subjects: 12
Study: 26014154

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 336

Group type: COMPARATOR
Intervention: Negative group
Number of subjects: 336
Study: 27709234

Group type: EXPERIMENTAL
Intervention: Home visit nutritional counselling
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Telephone consultation nutritional counselling
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group (no follow-up)
Number of subjects: 208
Study: 23689544

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BIS and DXA combined
Number of subjects: 36

Group type: COMPARATOR
Intervention: ECW/ICW measurement
Number of subjects: 36
Study: 20705561

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab (H0648g)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Chemotherapy (Control in H0648g)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy (H0649g)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Trastuzumab monotherapy (H0650g)
Number of subjects: 628
Study: 18192851

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg
Number of subjects: 6625

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6625
Study: 15928305

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment (8-10 mg/kg of body weight; 661 participants)
Number of subjects: 1285

Group type: COMPARATOR
Intervention: Placebo treatment (624 participants)
Number of subjects: 1285